Immix Biopharma, Inc. IMMX Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities.
The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immix Biopharma, Inc.'s change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immix Biopharma, Inc.'s change in accrued liabilities?
- Immix Biopharma, Inc. (IMMX) reported change in accrued liabilities of $432.21K in Q1 2026.
- How has Immix Biopharma, Inc.'s change in accrued liabilities changed year-over-year?
- Immix Biopharma, Inc.'s change in accrued liabilities increased by 67.1% year-over-year, from $258.72K to $432.21K.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.